Immune-checkpoint inhibitors targeting PD-1 or PD-L1 have already substantially improved
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …

Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged
as a targetable subset of breast tumors, based on the evidence from clinical trials of novel …

Immunotherapy with checkpoint inhibitors is well established as an effective treatment for
non-small cell lung cancer and melanoma. The list of approved indications for treatment with …

Abstract Programmed death ligand-1 (PD-L1) has been recently adopted for breast cancer
as a predictive biomarker for immunotherapies. The cost, time, and variability of PD-L1 …

Background In the phase III IMpassion130 study, atezolizumab plus nab-paclitaxel (A+ nP)
showed clinical benefit in advanced or metastatic triple-negative breast cancer patients who …

Simple Summary For decades, countless efforts have been devoted to developing targeted
drugs to improve the prognosis of triple-negative breast cancer (TNBC). Among the novel …

Breast cancer has historically been a disease for which immunotherapy was largely
unavailable. Recently, the use of immune checkpoint inhibitors (ICIs) in combination with …

Immunotherapy has emerged as the fifth pillar of cancer treatment alongside surgery,
radiotherapy, chemotherapy, and targeted therapy. Immune checkpoint inhibitors are the …

Abstract Programmed Death Ligand 1 (PD-L1) positivity rates differ between different
metastatic sites and the primary tumor. Understanding PD-L1 expression characteristics …

Triple negative breast cancer (TNBC) is a biologically diverse subtype of breast cancer
characterized by genomic and transcriptional heterogeneity and exhibiting aggressive …